A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

E. Cortes, Jörge; W. Kim, D.; Pinilla‐Ibarz, Javier; le Coutre, Philipp; Paquette, Ronald; Chuah, Charles; E. Nicolini, Franck; F. Apperley, Jane; Jean Khoury, H.; Talpaz, Moshe; F. DiPersio, John; J. DeAngelo, Daniel; Abruzzese, Elisabetta; Réa, Delphine; Baccarani, Michele; C. Müller, Martin; Gambacorti‐Passerini, Carlo; Wong, Siu‐Fun; Lustgarten, Stephanie; M. Rivera, Victor; Clackson, Tim; D. Turner, Christopher; G. Haluska, Frank; Guilhot, François; W. Deininger, Michael; Hochhaus, Andreas; P. Hughes, Timothy; M. Goldman, John; P. Shah, Neil; M. Kantarjian, Hagop

doi:10.1056/nejmoa1306494

Public

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Published in New England Journal of Medicine • Nov 1, 2013

Authors:

Jörge E. Cortes

D. W. Kim

Javier Pinilla‐Ibarz

Abstract

BACKGROUND: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leuk...

Subject

Ponatinib

Philadelphia chromosome

Myeloid leukemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!